Dr Dionysis Papadatos-Pastos

 Professional experience

• More than 20 years of experience
• Consultant Medical Oncologist, The London Clinic, Central London (present)
• Consultant Medical Oncologist, Leaders in Oncology Care (LOC), Central London (present)
• Consultant Medical Oncologist, University College London Hospitals NHS Foundation Trust (present)
• Consultant Medical Oncologist, Princess Alexandra Hospital NHS Foundation Trust, Harlow (present)
• Lead for lung cancer CRUK UCL Clinical Trials Centre
• joint lead for oncology, The Princess Alexandra Hospital

...

 Sub-specialties

• Lung cancer
• Mesothelioma
• Thymoma
• Immunotherapy
• Targeted therapies
• Chemotherapy

...

 Education

• PhD Medical Oncology University of Crete (2012)
• Degree in Medicine Athens University (2002)

 Publications and conferences

• First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors,Clin Cancer Res . 2020 Sep 15;26(18):4777-4784
• HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors, AACR Annual Meeting 2020; April 27-28, 2020
• Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit, Eur J Cancer . 2017 Apr;75:56-62
• A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors, Clin Cancer Res . 2012 May 1;18(9):2687-94
• Combining targeted therapeutics in the era of precision medicine, Br J Cancer 2015;112:1-3
• Delayed onset immune related adverse effects (IRAEs) of pembrolizumab in non-small cell lung cancer, 2019, ESMO Annual Meeting, 1510P
• A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma, 2011 ASCO annual meeting
• A first-in-human phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin’s lymphoma (NHL), 2010 ESMO annual meeting
• Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from phase I trials? The Royal Marsden Hospital Drug Development Unit experience. 2010 ASCO annual meeting 2010, received the ASCO foundation Merit Award.
• A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy. Clin Oncol (R Coll Radiol). 2024 Jan 16:S0936-6555(24)00025-6. doi: 10.1016/j.clon.2024.01.009. Online ahead of print.
• The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023 Apr;616(7957):525-533. doi: 10.1038/s41586-023-05783-5. Epub 2023 Apr 12. PMID: 37046096
• The evolution of non-small cell lung cancer metastases in TRACERx. Nature. 2023 Apr;616(7957):534-542. doi: 10.1038/s41586-023-05729-x. Epub 2023 Apr 12. PMID: 37046095
• Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. J Immunother Cancer. 2022 Jun;10(6):e004495. doi: 10.1136/jitc-2022-004495. PMID: 35717027 Free PMC article. Clinical Trial.

...

 Prizes and awards

• ASCO (American Society of Clinical Oncology) Merit Award (2010)

 Professional membership

• Royal College of Physicians
• Medical Defence Union
• General Medical Council

...